By Counterforce Health Team in Somatuline Depot (lanreotide) —

How to Get Somatuline Depot (Lanreotide) Covered by Blue Cross Blue Shield in Florida: 2025 Prior Authorization Guide

Answer Box: Getting Somatuline Depot Covered by Florida Blue

Florida Blue Cross Blue Shield requires prior authorization for Somatuline Depot (lanreotide) with 1-year approval for FDA-approved indications (acromegaly, GEP-NETs, carcinoid syndrome). Coverage criteria include documented inadequate response to octreotide, specialist oversight, and quantity limits of one syringe per 28 days. First step: Have your endocrinologist or oncologist submit PA via Availity.com or call 1-877-719-2583 with diagnosis, prior therapies, and lab results (IGF-1, GH suppression test). Appeals follow Florida's 180-day internal timeline plus external review through the Department of Financial Services.

Table of Contents

Policy Overview: How Florida Blue Handles Somatuline Depot

Florida Blue Cross Blue Shield (the state's largest insurer with 36% market share) treats Somatuline Depot as a Tier 4 specialty medication requiring prior authorization across all plan types. The drug appears on Florida Blue formularies including ValueScript Rx 2025 and Traditional Drug List 2024, typically with a $150 copay after deductible.

Plan-Specific Referral Requirements:

  • HMO plans (BlueCare, myBlue): Require PCP referral to endocrinologist/oncologist
  • PPO plans (BlueOptions, BlueChoice): Direct specialist access without referral

Florida Blue follows Medical Coverage Guideline MCG 09-J1000-20, updated July 2024, which aligns with FDA labeling and recognizes compendia-supported off-label uses.

Coverage at a Glance

Requirement Details Where to Find It
Prior Authorization Required for all indications Florida Blue PA portal
Formulary Tier Tier 4 specialty ($150 copay typical) Medication Guide
Step Therapy Inadequate response to octreotide MCG 09-J1000-20
Quantity Limits 1 syringe per 28 days (60-120 mg) Florida Blue formulary
Specialist Required Endocrinologist or oncologist Plan-dependent
Approval Duration 1 year initial, annual renewal MCG policy

Step-by-Step: Fastest Path to Approval

1. Verify Coverage & Network Status

Who: Patient
Action: Log into Florida Blue member portal → "Find Care Near Me" → locate in-network endocrinologist/oncologist
Timeline: Same day

2. Gather Required Documentation

Who: Patient + clinic staff
Documents needed:

  • Insurance card and policy details
  • Complete diagnosis with ICD-10 codes (E22.0 for acromegaly)
  • Prior octreotide therapy records and outcomes
  • Recent lab results (IGF-1, GH suppression test)
  • Pharmacy claims showing failed alternatives

3. Obtain Specialist Consultation

Who: Specialist (endocrinologist/oncologist)
Action: Document medical necessity, prior failures, contraindications
Timeline: 1-2 weeks for appointment

4. Submit Prior Authorization

Who: Provider
Method: Availity.com portal or call 1-877-719-2583
Include: Completed PA form, chart notes, labs, prior therapy documentation
Timeline: 5-14 business days for determination

5. Coordinate Specialty Pharmacy

Who: Provider + patient
Action: Once approved, coordinate with Florida Blue specialty pharmacy network
Timeline: 3-5 days for first shipment

6. Monitor and Prepare for Renewal

Who: Provider
Action: Document response (symptom improvement, lab normalization) for annual renewal
Timeline: Submit renewal 30 days before expiration

Medical Necessity Requirements

Florida Blue's medical necessity criteria align with FDA labeling and established clinical guidelines:

FDA-Approved Indications

  • Acromegaly: Confirmed diagnosis with inadequate surgical/radiation response
  • Gastroenteropancreatic NETs: Unresectable/metastatic well-differentiated tumors
  • Carcinoid syndrome: Associated with NET diagnosis

Documentation Requirements

  1. Diagnosis confirmation with appropriate ICD-10 coding
  2. Prior therapy failures: Documented inadequate response or intolerance to octreotide
  3. Clinical rationale: Specialist attestation of medical necessity
  4. Laboratory evidence: Baseline and monitoring labs (IGF-1, GH, chromogranin A)
  5. Treatment goals: Defined endpoints for response assessment
Clinician Corner: Medical necessity letters should include problem statement, prior treatments with specific outcomes, clinical rationale citing FDA labeling or NCCN guidelines, proposed dosing regimen, and monitoring plan.

Step Therapy & Exception Pathways

Florida Blue typically requires documented trial of octreotide (Sandostatin LAR) before approving Somatuline Depot. However, exceptions are granted for:

Medical Exceptions

  • Contraindications to octreotide (documented allergies, severe side effects)
  • Clinical superiority of lanreotide for specific patient factors
  • Prior authorization from another Blue plan within 2 years
  • Intolerance to octreotide injection site reactions or GI effects

Exception Documentation

Submit via standard PA process with additional supporting evidence:

  • Allergy documentation or adverse event reports
  • Specialist letter explaining clinical rationale
  • Previous authorization approvals (include dates and outcomes)

Quantity Limits & Dosing Rules

Florida Blue enforces quantity limits aligned with FDA dosing:

Strength Maximum Quantity Frequency Clinical Use
60 mg/0.2 mL 1 syringe Every 28 days Acromegaly (controlled)
90 mg/0.3 mL 1 syringe Every 28 days Acromegaly (standard)
120 mg/0.5 mL 1 syringe Every 28 days GEP-NETs, carcinoid

Dosing Adjustments: Extended intervals (6-8 weeks) may be approved for stable patients with documented response and specialist oversight.

Required Diagnostics & Documentation

Laboratory Requirements

  • Acromegaly: IGF-1 levels, GH suppression test, baseline pituitary function
  • NETs: Chromogranin A, 5-HIAA (if carcinoid), tumor markers
  • Imaging: Recent CT/MRI documenting tumor status
  • Timing: Labs within 90 days of PA submission

Documentation Best Practices

  1. Include reference ranges and normal values
  2. Show trend data demonstrating disease progression or control
  3. Correlate lab findings with clinical symptoms
  4. Document functional status and quality of life measures

Specialty Pharmacy Requirements

Somatuline Depot must be dispensed through Florida Blue's specialty pharmacy network:

  • Administration: Healthcare provider office only (not home use)
  • Storage: Refrigerated until administration
  • Coordination: Specialty pharmacy coordinates with provider for delivery timing
  • Refills: Automatic refill programs available with provider authorization

Contact Florida Blue Specialty Pharmacy Services at the number on your member ID card for network pharmacy options.

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
No prior octreotide trial Submit octreotide records or exception request Pharmacy claims, chart notes, specialist letter
Missing lab values Provide recent diagnostic results IGF-1, GH, imaging within 90 days
Non-specialist prescriber Transfer to endocrinologist/oncologist Referral, specialist consultation notes
Off-label use Cite compendia support NCCN guidelines, peer-reviewed literature
Quantity exceeded Adjust to formulary limits Revised prescription, clinical justification

Appeals Process in Florida

When Somatuline Depot is denied, Florida law provides structured appeal rights:

Internal Appeals (Level 1)

  • Timeline: 180 days from denial notice to file
  • Process: Submit via Florida Blue member portal or mail
  • Required: Denial letter, supporting clinical documentation, provider attestation
  • Decision: 30 days for non-urgent, 72 hours for expedited

External Review (Level 2)

  • Eligibility: After internal appeal denial or insurer failure to respond
  • Timeline: 4 months from final internal denial
  • Process: Contact Florida Department of Financial Services at 1-877-MY-FL-CFO
  • Cost: Free to consumer
  • Decision: Binding on insurer if overturned

Expedited Appeals

Available when delay could jeopardize health:

  • Can bypass internal appeal for urgent cases
  • 72-hour decision timeline
  • Requires physician attestation of urgency
Note: Keep detailed records of all communications, including dates, reference numbers, and names of representatives contacted.

Cost Assistance Options

Several programs can help reduce Somatuline Depot costs:

Manufacturer Support

  • Ipsen Cares Patient Assistance Program: Income-based free drug program
  • Copay savings card: Up to $10,000 annual assistance for eligible patients
  • Information: Visit Somatuline Depot patient resources

Foundation Grants

  • Patient Access Network Foundation: Covers copays for eligible NET patients
  • HealthWell Foundation: Assistance for rare disease treatments
  • Good Days: Copay and premium assistance programs

State Programs

Florida residents may qualify for additional assistance through state pharmaceutical programs for qualifying conditions.

From our advocates: "We've seen patients successfully appeal Somatuline Depot denials by gathering comprehensive octreotide trial documentation, including specific side effects and inadequate response data. The key is demonstrating that octreotide was genuinely tried and failed, not just briefly attempted. This approach, combined with strong specialist support, has helped overturn initial denials in similar cases."

Getting prescription drug approvals can feel overwhelming, especially for expensive specialty medications like Somatuline Depot. Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. The platform ingests denial letters, plan policies, and clinical notes to draft point-by-point rebuttals aligned to each plan's specific rules, pulling the right citations and clinical facts to support medical necessity arguments.

FAQ

How long does Florida Blue prior authorization take for Somatuline Depot?
Standard PA decisions take 5-14 business days. Expedited reviews (for urgent cases) are completed within 72 hours.

What if Somatuline Depot is non-formulary on my plan?
Submit a formulary exception request with clinical documentation showing medical necessity and failure of formulary alternatives.

Can I request an expedited appeal if my treatment is delayed?
Yes, if your physician attests that delay could jeopardize your health. Both internal and external expedited appeals are available in Florida.

Does step therapy apply if I failed octreotide outside of Florida?
Yes, pharmacy claims and medical records from any state are acceptable documentation of prior therapy failures.

What happens if I switch from another Blue Cross plan?
Florida Blue may honor prior authorizations from other Blue plans if within 2 years and for the same indication.

Can my primary care doctor prescribe Somatuline Depot?
While technically possible, Florida Blue's medical necessity criteria strongly favor specialist (endocrinologist/oncologist) prescribing for optimal approval chances.

How do I find an in-network specialist for my Florida Blue plan?
Use the "Find Care Near Me" tool on the Florida Blue website or call the customer service number on your member ID card.

What if my appeal is denied by Florida Blue?
You can request external review through the Florida Department of Financial Services within 4 months of the final internal denial. This review is free and binding if overturned.

For complex cases or when facing denials, consider partnering with Counterforce Health, which specializes in turning insurance denials into successful appeals by identifying specific denial reasons and crafting evidence-backed responses that meet each payer's unique requirements.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance policies vary by plan and change frequently. Always verify current coverage details with your insurer and consult healthcare professionals for medical decisions. For personalized assistance with insurance appeals and prior authorizations, consider consulting with qualified patient advocacy services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.